Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTX NASDAQ:KPTI NASDAQ:RNAC NASDAQ:WHWK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTXEntera Bio$1.23+6.0%$1.24$0.91▼$3.22$57.34M1.54210,445 shs93,061 shsKPTIKaryopharm Therapeutics$9.22-2.0%$8.02$3.65▼$10.99$207.93M0.8838,372 shs108,125 shsRNACCartesian Therapeutics$8.35+13.0%$6.87$5.60▼$15.57$245.79M0.58181,272 shs213,166 shsWHWKWhitehawk Therapeutics$4.20-0.2%$3.71$1.55▼$4.48$207.61M0.7165,095 shs71,297 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTXEntera Bio+5.45%+2.65%-7.94%-3.33%-49.34%KPTIKaryopharm Therapeutics+7.30%+9.42%+59.76%+49.37%+32.72%RNACCartesian Therapeutics+18.81%+8.68%+18.05%+8.04%-40.59%WHWKWhitehawk Therapeutics+5.51%+1.94%+19.94%+45.17%+420,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTXEntera Bio$1.23+6.0%$1.24$0.91▼$3.22$57.34M1.54210,445 shs93,061 shsKPTIKaryopharm Therapeutics$9.22-2.0%$8.02$3.65▼$10.99$207.93M0.8838,372 shs108,125 shsRNACCartesian Therapeutics$8.35+13.0%$6.87$5.60▼$15.57$245.79M0.58181,272 shs213,166 shsWHWKWhitehawk Therapeutics$4.20-0.2%$3.71$1.55▼$4.48$207.61M0.7165,095 shs71,297 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTXEntera Bio+5.45%+2.65%-7.94%-3.33%-49.34%KPTIKaryopharm Therapeutics+7.30%+9.42%+59.76%+49.37%+32.72%RNACCartesian Therapeutics+18.81%+8.68%+18.05%+8.04%-40.59%WHWKWhitehawk Therapeutics+5.51%+1.94%+19.94%+45.17%+420,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTXEntera Bio 2.00Hold$9.00631.71% UpsideKPTIKaryopharm Therapeutics 2.88Moderate Buy$16.1475.05% UpsideRNACCartesian Therapeutics 2.67Moderate Buy$34.00307.23% UpsideWHWKWhitehawk Therapeutics 2.50Moderate Buy$7.0066.67% UpsideCurrent Analyst Ratings BreakdownLatest ENTX, KPTI, RNAC, and WHWK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026KPTIKaryopharm Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $13.005/1/2026RNACCartesian Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$38.004/27/2026ENTXEntera Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $9.004/27/2026KPTIKaryopharm Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$8.00 ➝ $16.004/21/2026ENTXEntera Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/16/2026WHWKWhitehawk Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform4/16/2026WHWKWhitehawk Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$8.003/30/2026KPTIKaryopharm Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$12.00 ➝ $8.003/27/2026RNACCartesian Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026WHWKWhitehawk Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/25/2026KPTIKaryopharm Therapeutics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$21.00 ➝ $15.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTXEntera Bio$40K1,433.57N/AN/A$0.29 per share4.24KPTIKaryopharm Therapeutics$146.07M1.42N/AN/A($16.00) per share-0.58RNACCartesian Therapeutics$2.80M87.60N/AN/A($5.04) per share-1.66WHWKWhitehawk Therapeutics$7.14M29.08N/AN/A$2.89 per share1.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTXEntera Bio-$11.44M-$0.26N/AN/AN/AN/A-66.39%-57.77%5/8/2026 (Estimated)KPTIKaryopharm Therapeutics-$196.04M-$16.62N/AN/AN/A-134.21%N/A-122.29%5/11/2026 (Estimated)RNACCartesian Therapeutics-$130.30M-$5.90N/AN/AN/A-8,550.65%N/A-28.25%N/AWHWKWhitehawk Therapeutics-$20.60M$0.478.94N/AN/AN/A-62.88%-58.98%N/ALatest ENTX, KPTI, RNAC, and WHWK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026KPTIKaryopharm Therapeutics-$1.45N/AN/AN/A$31.40 millionN/A5/8/2026Q1 2026ENTXEntera Bio-$0.08N/AN/AN/AN/AN/A4/30/2026Q1 2026RNACCartesian Therapeutics-$0.84-$1.46-$0.62-$1.46$0.22 million$0.08 million3/27/2026Q4 2025ENTXEntera Bio-$0.09-$0.07+$0.02$0.07N/AN/A3/12/2026Q4 2025WHWKWhitehawk Therapeutics-$0.55-$0.34+$0.21-$0.34N/AN/A3/9/2026Q4 2025RNACCartesian Therapeutics-$0.82-$1.38-$0.56-$3.57$0.10 million$0.95 million2/13/2026Q4 2025KPTIKaryopharm Therapeutics-$2.26-$2.23+$0.03-$5.71$33.16 million$34.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthENTXEntera BioN/AN/AN/AN/AN/AKPTIKaryopharm TherapeuticsN/AN/AN/AN/AN/ARNACCartesian TherapeuticsN/AN/AN/AN/AN/AWHWKWhitehawk TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTXEntera BioN/A6.946.94KPTIKaryopharm TherapeuticsN/A1.121.08RNACCartesian TherapeuticsN/A7.657.65WHWKWhitehawk TherapeuticsN/A10.2610.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTXEntera Bio14.11%KPTIKaryopharm Therapeutics66.44%RNACCartesian Therapeutics86.95%WHWKWhitehawk Therapeutics52.08%Insider OwnershipCompanyInsider OwnershipENTXEntera Bio10.38%KPTIKaryopharm Therapeutics1.68%RNACCartesian Therapeutics60.30%WHWKWhitehawk Therapeutics49.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTXEntera Bio2046.62 million41.78 millionOptionableKPTIKaryopharm Therapeutics38022.54 million22.16 millionOptionableRNACCartesian Therapeutics6429.38 million11.67 millionOptionableWHWKWhitehawk Therapeutics2149.43 million24.76 millionN/AENTX, KPTI, RNAC, and WHWK HeadlinesRecent News About These CompaniesShort Interest in Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Increases By 12.4%May 3 at 3:29 AM | americanbankingnews.comWhitehawk Therapeutics, Inc. (NASDAQ:WHWK) Short Interest UpdateMay 1, 2026 | marketbeat.comWhitehawk Therapeutics (WHWK) price target increased by 10.29% to 6.38April 28, 2026 | msn.comWhitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026April 19, 2026 | prnewswire.comInsider Selling: Whitehawk Therapeutics (NASDAQ:WHWK) CFO Sells 77,000 Shares of StockApril 18, 2026 | insidertrades.comScott Giacobello Sells 77,000 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) StockApril 17, 2026 | marketbeat.comWhitehawk Therapeutics (NASDAQ:WHWK) CFO Scott Giacobello Sells 141,600 SharesApril 17, 2026 | marketbeat.comWhitehawk Therapeutics, Inc. Common Stock (WHWK) Institutional HoldingsApril 17, 2026 | nasdaq.comCitizens Initiates Coverage of Whitehawk Therapeutics (WHWK) with Market Outperform RecommendationApril 17, 2026 | msn.comWhitehawk jumps as Citizens issues Outperform rating ahead of trial dataApril 17, 2026 | seekingalpha.comWhitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat SeriesApril 16, 2026 | prnewswire.comCitizens Jmp Begins Coverage on Whitehawk Therapeutics (NASDAQ:WHWK)April 16, 2026 | marketbeat.comWhitehawk Therapeutics, Inc. (NASDAQ:WHWK) Given Consensus Rating of "Hold" by AnalystsApril 16, 2026 | marketbeat.comInsider Selling: Whitehawk Therapeutics (NASDAQ:WHWK) Insider Sells 26,389 Shares of StockApril 16, 2026 | insidertrades.comBryan Ball Sells 26,389 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) StockApril 15, 2026 | marketbeat.comBryan Ball Sells 92,460 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) StockApril 15, 2026 | marketbeat.comDiscovering Whitehawk Therapeutics Among 3 Promising Penny StocksApril 15, 2026 | finance.yahoo.comBryan Ball Sells 6,596 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) StockApril 14, 2026 | insidertrades.comBryan Ball Sells 6,596 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) StockApril 13, 2026 | marketbeat.comInsider Selling: Whitehawk Therapeutics (NASDAQ:WHWK) Insider Sells 50,000 Shares of StockApril 13, 2026 | marketbeat.comWhitehawk Therapeutics Inc.April 12, 2026 | barrons.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20263 Discounted Stocks With Strong Rebound PotentialBy Chris Markoch | April 6, 2026Tariffs Rose: 1 Steelmaker Thrived, 1 Still StrugglesBy Chris Markoch | April 23, 2026ENTX, KPTI, RNAC, and WHWK Company DescriptionsEntera Bio NASDAQ:ENTX$1.23 +0.07 (+6.03%) As of 02:18 PM Eastern This is a fair market value price provided by Massive. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Karyopharm Therapeutics NASDAQ:KPTI$9.22 -0.19 (-2.00%) As of 02:20 PM Eastern This is a fair market value price provided by Massive. Learn more.Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.Cartesian Therapeutics NASDAQ:RNAC$8.35 +0.96 (+12.98%) As of 02:20 PM Eastern This is a fair market value price provided by Massive. Learn more.Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.Whitehawk Therapeutics NASDAQ:WHWK$4.20 -0.01 (-0.24%) As of 02:19 PM Eastern This is a fair market value price provided by Massive. Learn more.Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage Years in the Making, AMD’s Upside Movement Has Just Begun Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Pinterest Pins a Profit Play To Its Mood Board Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
